H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

Provectus Pharmatech, Inc

Board Nf Regents the Inivercitvof Texas Cvctom

University of Texas System

Amod A Sarnaik

Mark L McLaughlin

Shari Pilon-Thomas

Hao Liu

Eric A Wachter

Jamie Singer

James J Mulé

Jeffrey S Weber

Laszlo G Radvanyi

Jessica Ann Chacon

MacLean S Hall

Shari Philon-Thomas

Mark Mclaughlin

Disclosed are compositions and methods for ex vivo expansion of tumor infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Tumor-infiltrating lymphocytes for adoptive cell therapy

Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.

Stabilized peptoid-peptide hybrids and uses thereof

A cancer immunotherapy method is disclosed in which 'induced immune anticancer agents' are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

Growing community of inventors

Tampa, FL, United States of America

Amod A Sarnaik